1. Introduction {#sec1}
===============

Influenza viruses (IV) cause substantial morbidity and mortality through routine seasonal spread and epidemics.^[@ref1],[@ref2]^ At present, the first-line drugs recommended for antiflu treatment are NA inhibitors.^[@ref3]−[@ref5]^ However, the antiviral drugs have met several limitations because of the high frequency of emerging resistant variants and undesirable toxic side effects.^[@ref6],[@ref7]^ Therefore, there is a continuous and urgent need to develop novel and effective drugs to overcome the limitations of the existing antiviral agents.

Here, we reported a novel series of butenolides with anti-influenza activity H1N1 in vitro and in vivo. Among all synthetic compounds, compound **37** showed the most significant antivirus activity with an EC~50~ of 6.7 μM as an inhibitor of NA from influenza A virus H1N1with low cytotoxic on MDCK cells. The antiviral activity of compound **37** was also verified in vivo. The viral loads in lung tissues of the groups treated by compound **37** were lower than that of the model group by qRT-PCR analysis.

The γ-butenolide is a ubiquitous structural component present in a plethora of naturally occurring compounds ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref8]^ Some of them showed high efficiency against viruses including HBV, HCV, BVDV, and anti-influenza virus activities such as compound **I**.^[@ref9]−[@ref11]^ In our preliminary research, we focused on the synthesis and bioactive research of butenolide derivatives and found that compound **II** showed anti-BVDV activity. Based on the work above, screening of these compounds via an in-house compound library showed the potency of a novel butenolide (**25**) for inhibiting influenza A virus H1N1 with an IC~50~ of 61 μM. With compound **25** as a hit compound, a series of novel butenolide derivatives were designed and synthesized to study the SAR by modification at the α-, β-, and γ-carbons of carbonyl on butenolide.

![Structures of butenolide derivatives.](ao9b01421_0006){#fig1}

2. Results and Discussion {#sec2}
=========================

2.1. Syntheses of Target Compounds {#sec2.1}
----------------------------------

First, compounds **22**--**30** were designed and synthesized to investigate the contribution to activity of substitution on the phenyl group at the α-carbon of butenolide. The syntheses of compounds **22**--**30** were shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The substituted phenyl acetic acids (**1**) were treated with ethyl chloroacetate (**2**) to afford the acyclic ester (**3**), which then underwent an intramolecular cyclization to afford the 2-phenyl-3-hydroxybutenolides (**4**--**12**). Compounds **4**--**12** were then converted to their 4-methoxy derivatives **13**--**21** by a methylation reaction. Compounds **13**--**21** were used to prepare 2-phenyl-3,4-dimethoxy-4-methylbutenolides (**22**--**30**) through condensation with paraformaldehyde in methanol in the presence of CH~3~ONa.

![Synthesis of Compounds **22**--**30**\
Regents and conditions: (a) (Et)~3~N, THF, 75 °C, and \>90%; (b) *t*-BuOK, DMF, from 0 °C to room temperature, and 80--90%; (c) Me~2~SO~4~, K~2~CO~3~, Acetone, and 70--80%; and (d) (CH~2~O)*~n~*, CH~3~ONa, CH~3~OH, 75 °C, and 45--50%.](ao9b01421_0001){#sch1}

Compounds **37**--**41** were designed and synthesized to compare the heterocyclic and benzylamine substitution with methoxy at the β-carbon ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Compound **9** was treated with oxalyl chloride in DMF and DCM to yield compound **31**, which was used to prepare compounds **32**--**36** by the reaction with a morpholine analogous or benzylamine. Compounds **36**--**41** were obtained by refluxing with paraformaldehyde in the presence of NaOCH~3~ in methanol.

![Synthesis and Structures of Compounds **36**--**41**\
Reagent and conditions: (a) oxalyl chloride, DMF/CH~2~Cl~2~ (1:1) as well as 95%; (b) morpholine analogous or benzylamine, K~2~CO~3~, THF, and 78%; and (c) (CH~2~O)*~n~*, CH~3~ONa, CH~3~OH, 75 °C, and 30--40%.](ao9b01421_0002){#sch2}

Keeping the groups on α- and β-carbons, compounds **45**--**48** were designed to investigate the phenyl hydroxymethyl substitution contribution for their antivirus activity. The key mediate **44** was synthesized by the reaction with ethyl 2-bromopropanoate and compound **1d** as raw materials ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). It was treated with various aryl aldehydes to give compounds **45**--**48**.

![Synthesis of Compounds **45**--**48**\
Regents and conditions: (a) (Et)~3~N, THF, and 75 °C; (b) *t*-BuOK, DMF, from 0 °C to room temperature, and 80--90% for two steps; (c) Me~2~SO~4~, K~2~CO~3~, Acetone, and 70--80%; and (d) aryl aldehyde, CH~3~ONa, CH~3~OH, and 40--50%.](ao9b01421_0003){#sch3}

Based on the primary screening of the synthetic compounds for influenza A H1N1, compound **37** showed an improved antivirus activity. Thus, compounds **57**--**60** were designed and prepared to evaluate the contribution of various substitutions such as chlorine, fluorin, and methyl groups on the phenyl at the α-carbon to compare with compound **37**. They were synthesized by the similar reactions used for the preparation of compound **37** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Among them, compound **59** was characterized by an X-ray diffraction analysis (CCDC 1844567).

![Synthesis and Structures of Compounds **57**--**60**\
Reagent and conditions: (a) oxalyl chloride, DMF/CH2Cl2 (1:1), and 95%; (b) morpholine, K~2~CO~3~, THF, and 78%; and (c) (CH~2~O)*~n~*, CH~3~ONa, CH~3~OH, 75 °C, and 30--40%.](ao9b01421_0007){#sch4}

2.2. Synthetic Compounds and their Anti-Influenza A Virus H1N1 Activity In Vitro {#sec2.2}
--------------------------------------------------------------------------------

All the synthetic compounds were evaluated by anti-influenza A H1N1 virus activity in MDCK cell ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). A better antivirus activity was found on compounds **22**, **23**, **27**, **28**, and **30** than the hit compound **25** with an EC~50~ of 7.5 ± 0.9 to 33.4 ± 1.0 μM. Compounds **27** and **28** with *m*-F and *p*-methoxyl phenyl groups have a similar level EC~50~ of 7.5 and 9.4 μM. Compounds **36**--**40** with *p*-methoxyl phenyl groups at α-carbon and amino groups at the β position showed effective antiviral activity. Among them, compound **37** was the best one. However, compounds **45**--**48** with the phenyl hydroxymethyl substitution at the γ-carbon showed almost no antivirus activity. Compounds **57**--**60** designed according to compound **37** showed efficient antiviral activity with an EC~50~ of 14.1 ± 2.5 to 34.7 ± 5.9 μM, although no compound was better than compound **37**.

###### Anti-Influenza A H1N1 Activity on MDCK, Cytotoxicity of Synthetic Compounds

  ID                                   R                     EC~50~ (μM)[a](#t1fn1){ref-type="table-fn"}[a](#t1fn1){ref-type="table-fn"}, [f](#t1fn6){ref-type="table-fn"}   CC~50~ (μM)[b](#t1fn2){ref-type="table-fn"}   SI[c](#t1fn3){ref-type="table-fn"}   tPSA[d](#t1fn4){ref-type="table-fn"}   cLogP[h](#t1fn8){ref-type="table-fn"}
  ------------------------------------ --------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------ -------------------------------------- ---------------------------------------
  **22**                               H                     26.3 ± 4.4                                                                                                      168.1 ± 9.7                                   6.4                                  44.76                                  2.10
  **23**                               *p***-**F             16.2 ± 1.7                                                                                                      736.0 ± 69.6                                  46.0                                 44.76                                  2.26
  **24**                               *p***-**Cl                                                                                                                            98.3 ± 3.5                                                                         44.76                                  2.82
  **25**                               *p***-**Br            61.1 ± 5.0                                                                                                      266.0 ± 18.4                                  13.9                                 44.76                                  2.97
  **26**                               *p***-**CH~3~                                                                                                                         183.8 ± 5.1                                   **-**                                44.76                                  2.60
  **27**                               *p***-**OCH~3~        7.5 ± 0.9                                                                                                       307.2 ± 19.3                                  40.9                                 53.99                                  2.02
  **28**                               *m***-**F             9.4 ± 0.8                                                                                                       19.8 ± 1.0                                    2.1                                  44.76                                  2.25
  **29**                               *o***-**F                                                                                                                             204.3 ± 3.2                                                                        44.76                                  2.25
  **30**                               *m***-**,*p***-**2F   33.4 ± 1.0                                                                                                      108.9 ± 7.6                                   3.2                                  44.76                                  2.32
  **37**                                                     6.7 ± 1.3                                                                                                       536.3 ± 15.1                                  85.6                                 57.23                                  2.00
  **38**                                                     25.6 ± 0.4                                                                                                      355.0 ± 21.2                                  13.8                                 48.00                                  2.93
  **39**                                                     \>100                                                                                                           507.6 ± 25.3                                                                       68.23                                  1.39
  **40**                                                     25.9 ± 0.1                                                                                                      304.9 ± 7.2                                   11.8                                 68.23                                  2.07
  **41**                                                                                                                                                                     23.5 ± 1.9                                                                         56.79                                  4.16
  **45**                                                                                                                                                                     185.8 ± 7.8                                                                        55.76                                  4.57
  **46**                                                                                                                                                                     75.2 ± 3.6                                                                         55.76                                  4.36
  **47**                                                                                                                                                                     154.8 ± 6.8                                                                        68.12                                  2.36
  **48**                                                                                                                                                                     129.8 ± 8.1                                                                        68.23                                  3.32
  **57**                               *p***-**F             14.3 ± 1.7                                                                                                      776.2 ± 63.2                                  54.2                                 48.00                                  2.22
  **58**                               *p***-**Cl            34.7 ± 5.9                                                                                                      209.4 ± 14.1                                  6.0                                  48.00                                  2.79
  **59**                               *p***-**CH~3~         14.1 ± 2.5                                                                                                      218.7 ± 8.7                                   15.6                                 48.00                                  2.58
  **60**                               *m***-**F                                                                                                                             146.6 ± 8.1                                                                        48.00                                  2.33
  Ri[g](#t1fn7){ref-type="table-fn"}                         105.0 ± 51.0                                                                                                    532.0 ± 20.3                                  5.1                                                                          
  Os[h](#t1fn8){ref-type="table-fn"}                         0.28 ± 0.05                                                                                                     \>800                                                                                                                      

Concentration for 50% of inhibition of H1N1A/Weiss/**43**.

Concentration for 50% of cytotoxicity on MDCK.

SI = CC~50~/EC~50~.

tPSA is topological polar surface area, which was predicted by Chemdraw.

cLogP is calculated LogP, which is an octanol--water partition coefficient.

No activity in the ID **24** tested concentration range of 5--100 μM.

Ribavirin.

Oseltamivir.

Based on the results above, the SAR is analyzed and suggests that the substitution of halogen and methoxy on the phenyl group at the α-carbon of carbonyl on butenolide are beneficial to antivirus activity for compounds **22**--**30**. Specially, compounds **27** and **28** with *m*-F and *p*-methoxyl phenyl groups are better than others. The amino groups at the β-carbon of the carbonyl group contribute to the antivirus activity for compounds **37**--**41**. Among them, compound **37** with morpholine substitution is the best one. The methoxy at the γ-carbon of the carbonyl group showed an important role for the antivirus of the novel butenolides. Introduction of phenyl hydroxymethyl groups such as compounds **45**--**48** led to the loss of antivirus activity.

2.3. Inhibition of Compound **37** against NA from Influenza A Virus H1N1 {#sec2.3}
-------------------------------------------------------------------------

A fluorescence-based NA inhibition assay was used to determine whether the compounds have the abilities to suppress NA activity. The inhibition rate of compound **37** was increased in a dose-dependent manner, closely to the neuraminidase inhibitors of oseltamivir in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. It revealed that compound **37** could decrease neuraminidase activity and inhibit the virus as a novel NA inhibitor.

![Inhibition of NA activity of compound **37** and oseltamivir.](ao9b01421_0011){#fig2}

2.4. Cytotoxicity and Antiviral Activity of Compound **37** on MDCK Cells {#sec2.4}
-------------------------------------------------------------------------

Cytotoxicity and antiviral activity of compound **37** on MDCK cells were shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. Compound **37** had less cytotoxicity on MDCK cells, and there were low cytotoxic effect on the viability of MDCK cells even at a concentration of 800 μM ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). The inhibition on infected MDCK cells was in dose-dependent ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Among the synthetic compounds, compound **37** showed better antivirus activity than positive control ribavirin. These results suggest that the compound **37** had a better antiviral activity on MDCK cells.

![Cytotoxicity and antiviral activity of compound **37** on MDCK cells. (A) Cytotoxicity of compound **37**. (B) Antiviral activity of compound **37**.](ao9b01421_0010){#fig3}

2.5. Anti-Influenza A Virus H1N1 Activity of Compound **37** In Vivo {#sec2.5}
--------------------------------------------------------------------

Thus, compound **37** was chosen to test the anti-influenza A virus activity on SPF KM mice. As shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, the body temperature was fluctuated at 36.5 °C, and the body weight was increased in all groups before virus infection. Whereas, the body temperature and body weight in the virus group were decreased after virus infection from 4 to 8 days. Meanwhile, the body temperatures treated with compound **37** was closed to the control groups. The body weights of the high-dose group treated by compound **37** kept increasing and were closely to the control group.

![Changes in body temperature and body weight of mice (*n* = 8).](ao9b01421_0009){#fig4}

As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}, no lesion (pink color) could be observed in the lung of mice without the treatment of virus ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). However, obvious lesion (dark red) was found, and the volume of the lung was increased in the virus group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). Basically, less lesion were found in the groups of compound **37** compared to the virus control ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C,D). The antiviral efficacy was also confirmed microscopically by hematoxylin--eosin (H&E) staining. No inflammation or pathological changes of the lung was observed in the normal control group. Severe lung hyperemia, lesions, and alveolar walls thickened were observed in the virus group. Meanwhile, many inflammatory infiltrates of lymphocytes, neutrophils, and macrophages were also filled in alveolar spaces of the virus group. However, less lung inflammation and lesions were observed in the groups of compound **37**. These data reveal that compound **37** had the antiviral effect against H1N1.

![Gross lesions and Histopathological changes in lungs. The lungs were sectioned for H&E staining, and images were taken at ×200 magnification. (A) Control, (B) virus, (C) compound **37** (200 mg/kg), and (D) compound **37** (50 mg/kg).](ao9b01421_0005){#fig5}

The viral loads of normal , virus , treatment groups were analyzed by a quantitative real-time RT-PCR (qRT-PCR) in the lung tissue. Lower viral loads were detected in the group treated by compound **37** compared to the virus group ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The results suggest that compound **37** was able to decrease the virus load in the lung tissue.

![Expression of virus gene in lungs determined by qRT-PCR (*n* = 8). \**P* \< 0.05 compared to virus.](ao9b01421_0008){#fig6}

Based on the natural butenolide skeleton and screening of an in-house compound library, compound **37** as an antiviral agent was obtained by optimization of the hit compound. It could inhibit the activity of influenza A virus H1N1 in vitro and in vivo. Also, it could reduce the activity of NA. These results suggest that compound **37** could inhibit the H1N1 via suppressing the virus target of NA.
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